

# To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

NCT06204991

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Inge Marie Svane
Enrollment	10 participants

## Plain Language Summary

---

This trial tests ADP-TILIL7 — a treatment that takes immune cells (called TILs) from a patient's own tumor, grows them in the lab with a molecule called IL-7, and infuses them back to fight cancer — for people with advanced melanoma (skin cancer) that stopped responding to standard immunotherapy.

**\*\*You may be eligible if...\*\***

- You have inoperable or metastatic melanoma (stage IIIC or IV)
- Your cancer progressed after treatment with PD-1 immunotherapy (such as pembrolizumab or nivolumab), with or without CTLA-4 therapy
- You are between 18 and 75 years old
- You have a tumor large enough (over 1 cm<sup>3</sup>) that can be surgically removed to make the TIL treatment
- You have at least one other measurable tumor site remaining after the removal
- Your heart function is adequate (ejection fraction of 50% or more)

**\*\*You may NOT be eligible if...\*\***

- You are not fit enough for surgery to remove tumor tissue
- You do not have a measurable tumor site outside the one to be resected
- Your general health is poor (ECOG above 1)
- You have serious heart, liver, or organ function issues

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (31)

- All the criteria listed in the following need to be met before patient inclusion.
- Histologically confirmed inoperable or metastatic melanoma (stage IIIC or IV).
- Progressive disease after standard treatment with PD-1 check-point inhibition or combination of aforementioned with CTLA-4 check-point inhibition.
- Age: 18 - 75 years at time of signed Informed consent.
- ECOG performance status of d 1 (Appendix 2).

... and 26 more (see full listing online)

### Exclusion (31)

- Patients will be excluded if they meet one of the criteria's listed below
- Subject has received or plans to receive the following therapy/treatment prior to tumor resection (TR) or lymphodepleting chemotherapy (LDC):
- Cytotoxic chemotherapy: Washout period 3 weeks before TR and LDC

- Small molecules/TKI: Washout period 1 week before TR and LDC

<https://clinicaltrials.gov/study/NCT06204991>

- Immune therapy (monoclonal AB therapy, CPI and biologics): 2 weeks before TR and LDC

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

... and 26 more (see full listing online)

## Locations (2 total)

---

Department of Oncology, Herlev, Denmark

Department of Oncology, Herlev, Denmark

---

<https://clinicaltrials.gov/study/NCT06204991>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://ClinicalTrialsFinder.org).